Jessica Fye

Stock Analyst at JP Morgan

(3.87)
# 705
Out of 4,495 analysts
105
Total ratings
54.55%
Success rate
7.28%
Average return

37 Stocks

Alkermes
Jul 15, 2024
Maintains: Neutral
Price Target: $32$31
Current: $24.60
Upside: +26.02%
Immunocore Holdings
Jul 10, 2024
Maintains: Overweight
Price Target: $70$66
Current: $41.49
Upside: +59.07%
Denali Therapeutics
Jul 10, 2024
Maintains: Overweight
Price Target: $28$29
Current: $23.94
Upside: +21.14%
Crinetics Pharmaceuticals
Jul 9, 2024
Maintains: Overweight
Price Target: $47$54
Current: $54.98
Upside: -1.78%
Alnylam Pharmaceuticals
Jul 3, 2024
Maintains: Neutral
Price Target: $160$248
Current: $249.83
Upside: -0.73%
Insmed
Jun 20, 2024
Maintains: Overweight
Price Target: $55$72
Current: $77.98
Upside: -7.67%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $31$39
Current: $40.00
Upside: -2.50%
Intra-Cellular Therapies
Jun 12, 2024
Maintains: Overweight
Price Target: $75$78
Current: $78.57
Upside: -0.73%
United Therapeutics
May 21, 2024
Maintains: Overweight
Price Target: $280$300
Current: $328.19
Upside: -8.59%
Ascendis Pharma
May 3, 2024
Maintains: Overweight
Price Target: $167$170
Current: $140.80
Upside: +20.74%
Stoke Therapeutics
Mar 26, 2024
Maintains: Neutral
Price Target: $6$13
Current: $14.74
Upside: -11.80%
BioNTech SE
Mar 22, 2024
Maintains: Underweight
Price Target: $99$90
Current: $86.82
Upside: +3.66%
Jazz Pharmaceuticals
Mar 22, 2024
Maintains: Overweight
Price Target: $170$190
Current: $106.09
Upside: +79.09%
BeiGene
Mar 19, 2024
Maintains: Overweight
Price Target: $184$186
Current: $152.92
Upside: +21.63%
NovoCure
Mar 19, 2024
Maintains: Neutral
Price Target: $15$17
Current: $19.28
Upside: -11.83%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $438$450
Current: $488.98
Upside: -7.97%
Ionis Pharmaceuticals
Feb 1, 2024
Maintains: Neutral
Price Target: $52$55
Current: $49.84
Upside: +10.35%
Cerevel Therapeutics Holdings
Dec 28, 2023
Maintains: Neutral
Price Target: $25$45
Current: $42.45
Upside: +6.01%
Moderna
Dec 1, 2023
Maintains: Neutral
Price Target: $93$90
Current: $125.14
Upside: -28.08%
Nektar Therapeutics
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.47
Upside: -
Emergent BioSolutions
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $12.11
Upside: -
Esperion Therapeutics
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.73
Upside: -
Amarin Corporation
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.79
Upside: -
BioCryst Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.63
Upside: +31.06%
Legend Biotech
Apr 19, 2023
Maintains: Overweight
Price Target: $65$76
Current: $55.90
Upside: +35.96%
Halozyme Therapeutics
Feb 23, 2023
Maintains: Overweight
Price Target: $54$52
Current: $55.10
Upside: -5.63%
Incyte
Feb 8, 2023
Maintains: Neutral
Price Target: $82$80
Current: $64.00
Upside: +25.00%
BioMarin Pharmaceutical
Oct 24, 2022
Maintains: Overweight
Price Target: $140$112
Current: $85.89
Upside: +30.40%
Cara Therapeutics
Mar 8, 2022
Upgrades: Overweight
Price Target: $17$20
Current: $0.37
Upside: +5,305.41%
Aprea Therapeutics
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.01
Upside: -
LAVA Therapeutics
Apr 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $2.11
Upside: -
Lexicon Pharmaceuticals
Jan 29, 2021
Upgrades: Neutral
Price Target: n/a
Current: $2.23
Upside: -
Mersana Therapeutics
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $2.25
Upside: -
Novavax
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $16.44
Upside: -
Radius Health
Nov 2, 2018
Maintains: Overweight
Price Target: n/a
Current: $17.87
Upside: -
Chimerix
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $0.95
Upside: -
Enanta Pharmaceuticals
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $16.15
Upside: -